- Technology company EnWave (ENW) has announced a collaboration to develop an inhaler which provides relief to COVID-19 patients
- The company will work with the University of British Columbia (UBC) to explore possible manufacturing methods for the inhaler
- EnWave’s Radiant Energy Vacuum (REV) dehydration technology may be a plausible drying method for encapsulating microparticles into inhalable treatments
- Researchers from the company’s collaboration with UBC will assess the REV technology’s feasibility for the project
- EnWave (ENW) is down 4.26 per cent and is currently trading at C$0.90 per share
Technology company, EnWave (ENW) has announced a collaboration to develop an inhaler which provides relief to COVID-19 patients.
The company will work with the University of British Columbia (UBC) to explore possible manufacturing methods for the inhaler. The project is primarily being funded through a C$50,000 NSERC Alliance government research grant.
As the COVID-19 pandemic continues to ravage nations around the world, the race is on to develop a vaccine or cure for the virus. In the meantime, this project aims to create an inhalable treatment that will provide some relief to people suffering from its effects.
Researchers at UBC are looking for a drying method which will encapsulate microparticles of angiotensin-converting enzyme 2 (ACE2) into that inhalable treatment. This process, if achieved, would improve the delivery and absorption of the drug.
EnWave’s Radiant Energy Vacuum (REV) dehydration technology may present a plausible drying method for the manufacturing process. As such, researchers from the company and UBC will assess the REV technology’s feasibility for the project.
The research team hopes to generate the first prototypes of encapsulated ACE2 by the end of summer. During this time, project collaborators in both Sydney and Vancouver will gather data on ACE2’s toxicology in lung tissue.
EnWave’s CEO, Brent Charleton, commented on the company’s application of its REV technology in this important initiative.
“The innovative nature of our proprietary drying technology could support a breakthrough in the commercial feasibility of the COVID-19 treatment that our UBC collaborators have been developing.
“We hope that this project will lead to a viable treatment against COVID-19 and help strengthen the fight against this pandemic,” he said.
EnWave (ENW) is down 4.26 per cent and is trading at $0.90 per share at 2:34pm EDT.